Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued

Preclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy

Read more at globenewswire.com